Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Update on targeted therapies for Philadelphia-like ALL

ALL Assembly 2018

Published: 18 Oct 2018

Views: 1562

Rating:

Save

Prof Stephen Hunger - Children’s Hospital of Philadelphia, Philadelphia, USA

Prof Stephen Hunger talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about the targeted therapies for Philadelphia-like ALL.

Prof Hunger discusses some of the key questions surrounding targeted therapies for Philadelphia-like ALL and how to show it improves outcomes.

He also considers how to treat T-cell ALL and whether or not technological advances will alter the landscape for treatment in the near future.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related Videos

Digital pathology superior to manual SP263 PD-L1 TC scoring for stage II-IIIA high PD-L1 expression NSCLC

Prof Martin Reck - German Center of Lung Research, Grosshansdorf, Germany

Digital pathology superior to manual SP263 PD-L1 TC scoring for stage II-IIIA high PD-L1 expression NSCLC ( Prof Martin Reck - German Center of Lung Research, Grosshansdorf, Germany )

AI in multiple myeloma: Recent findings and opportunities

Prof Anant Madabhushi - Emory University, Atlanta, USA

AI in multiple myeloma: Recent findings and opportunities ( Prof Anant Madabhushi - Emory University, Atlanta, USA )

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM

Dr Jill Corre - IUCT Oncopole, Toulouse, France

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )

Revolutionising myeloma treatment through immune profiling

Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA

Revolutionising myeloma treatment through immune profiling ( Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA )

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )

Addressing the rise of multiple myeloma in Rwanda

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Addressing the rise of multiple myeloma in Rwanda ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

EHA 2024: Multiple myeloma roundup

Dr Claudio Cerchione - IRCCS, Meldola, Italy

EHA 2024: Multiple myeloma roundup ( Dr Claudio Cerchione - IRCCS, Meldola, Italy )

Synthetic biology and precision medicine in blood and gynaecological cancers

Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa

Synthetic biology and precision medicine in blood and gynaecological cancers ( Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa )

ALLO-316 demonstrates encouraging anti-tumour activity for patients with advanced or metastatic ccRCC

Dr Samer Srour - The University of Texas MD Anderson Cancer Center, Houston, USA

ALLO-316 demonstrates encouraging anti-tumour activity for patients with advanced or metastatic ccRCC ( Dr Samer Srour - The University of Texas MD Anderson Cancer Center, Houston, USA )

More from ecancer